Page 53 - Strategies for non-invasive managementof high-grade cervical intraepithelial neoplasia - prognostic biomarkers and immunotherapy Margot Maria Koeneman

A review of prognostic biomarkers
2
51
Biomarker group
Biomarker
Assumed role in natural history of CIN
Studied in histologically confirmed CIN?
No of studies Prospective Study on high-grade study design? size CIN (incl CIN 2) (n=)
Evaluation according to the PROBE-criteria*
Effect
IMP-3
Oncoprotein, expressed only in fetal tissues and malignancies. No previous studies on role in cervical oncogenesis.
CIN 2-3
1 (83) No, 710 retrospective
1. +/- 2. +/- 3. + 4. -
IMP3 expression
is associated with disease progression to invasive carcinoma.
Zinc finger protein 441
Transcription regulator, functioning as tumour suppressor. No previous studies on role in cervical oncogenesis.
Yes, CIN 2-3
1 (84) Yes 40
1. + 2. +/- 3.+ 4. -
ZFP-441 expression is associated with disease regression.
Phospholipase D6
Involved in cell proliferation, may induce epigenetic effects. No previous studies on role in cervical oncogenesis.
Yes, CIN 2-3
1 (84) Yes 40
1. + 2. +/- 3.+ 4. -
PD6 is associated with disease regression.
*Evaluation according to the PROBE criteria was only performed for biomarkers that were studied in histologically conformed high-grade CIN (including CIN 2). Evaluation was done for each individual study on a biomarker and is presented as +, +/- or - for each study. PROBE criteria include: 1. Components of design relating to clinical context; 2. Components of design relating to performance criteria; 3. Components of design relating to the biomarker; 4. Components of design relating to study size. In bold are those biomarker that have been selected by the reviewers as deserving special attention.
analysis